Adipose Insulin Resistance and Decreased Adiponectin Are Correlated With Metabolic Abnormalities in Nonobese Men.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
23 04 2021
Historique:
received: 09 10 2020
pubmed: 24 1 2021
medline: 28 9 2021
entrez: 23 1 2021
Statut: ppublish

Résumé

Adipose tissue dysfunction is characterized by decreased adiponectin (AN) levels and impaired adipose tissue insulin sensitivity (ATIS) and is associated with metabolic disorders. While Asians readily develop metabolic disease without obesity, it remains unclear how decreased AN level and impaired ATIS affect metabolic abnormalities in nonobese Asians. To investigate the relationships between decreased AN level, impaired ATIS, and metabolic abnormalities, we studied 94 Japanese men whose body mass index was less than 25 kg/m2. We divided the subjects into 4 groups based on their median AN level and ATIS, the latter calculated as the degree of insulin-mediated suppression of free fatty acids during hyperinsulinemic euglycemic clamp, and compared the metabolic parameters in the 4 groups. The High-ATIS/High-AN group (n = 29) showed similar anthropometric data to the High-ATIS/Low-AN group (n = 18). In contrast, both the Low-ATIS/High-AN (n = 18) and Low-ATIS/Low-AN (n = 29) groups showed significantly lower muscle insulin sensitivity than the High-ATIS groups. The intrahepatic lipid level in the Low-ATIS/Low-AN group was significantly higher than that in the High-ATIS groups. In addition, the Low-ATIS/Low-AN group had a significantly higher fasting serum triglyceride level and significantly lower high-density lipoprotein cholesterol level than the other 3 groups. In nonobese Japanese men with high ATIS, the AN level was not associated with metabolic characteristics. On the other hand, subjects with low ATIS showed reduced muscle insulin sensitivity, and those with a decreased AN level demonstrated multiple metabolic abnormalities, represented by fatty liver and dyslipidemia.

Identifiants

pubmed: 33484562
pii: 6117790
doi: 10.1210/clinem/dgab037
doi:

Substances chimiques

Adiponectin 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2228-e2238

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Mai Kiya (M)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Yoshifumi Tamura (Y)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Kageumi Takeno (K)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Yuki Someya (Y)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Saori Kakehi (S)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Motonori Sato (M)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Nozomu Yamasaki (N)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Satoshi Kadowaki (S)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Ruriko Suzuki (R)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Yasuhiko Furukawa (Y)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Daisuke Sugimoto (D)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Hideyoshi Kaga (H)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Takashi Funayama (T)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Miho Nishitani-Yokoyama (M)

Department of Cardiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Kazunori Shimada (K)

Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Department of Cardiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Hiroyuki Daida (H)

Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Department of Cardiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Shigeki Aoki (S)

Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Hiroaki Satoh (H)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Ryuzo Kawamori (R)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Hirotaka Watada (H)

Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Center for Identification of Diabetic Therapeutic Targets, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Center for Molecular Diabetology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH